Research work · 2022
Precision medicine in Australia: now is the time to get it right
The Medical Journal of Australia
Abstract
Precision medicine is a tailored approach to health, incorporating an individual’s genetic makeup, environment and lifestyle, and is a new frontier offering much promise for disease prevention and cure.1 Its recent rise has been largely driven by rapid advances in genomic medicine, with sequencing of an individual’s genetic code identifying opportunities for precision health care, therapies and diagnostics. Genomics has revolutionised many areas, including public health (eg, population genetic carrier screening and pathogen genomic sequencing during the coronavirus disease 2019 [COVID19] pandemic), pharmacogenomics (drug metabolism and response genes), cancer management (tumour sequencing for diagnosis and therapy targets), pregnancy management (testing, screening and preimplantation genetic diagnosis) and rare diseases (Box 1). Medicare item numbers are now approved for genomic diagnostics in cancer, preimplantation genetic diagnosis, and certain paediatric, renal and cardiac conditions. New genetic therapies have arisen, including Therapeutic Goods Administration (TGA)funded ocular (voretigene neparvovec; Luxturna, Novartis), neuromuscular (onasemnogene abeparvovec; Zolgensma, Novartis), oncological (tisagenlecleucel; Kymriah, Novartis) and other genetic therapies.
DOI: 10.5694/mja2.51777